Quantinuum Q3 2026 Earnings: Revenue Triples as Losses Widen

Quantinuum (Nasdaq: QNT) reported Q3 2026 revenue of $9.1 million for the quarter ended September 30, up 233% from $2.7 million a year earlier, while GAAP basic and diluted loss per Class A share was $0.46. GAAP gross margin turned positive, but higher operating expenses pushed both GAAP and adjusted losses wider. The company raised its full-year revenue outlook as commercial agreements and platform adoption advanced.

Core Results

Revenue more than tripled year over year, helping GAAP gross profit improve to $3.0 million from a $1.2 million loss. Adjusted gross margin also increased to 74.6%, indicating that the improvement was not limited to GAAP accounting effects.

The larger revenue base did not offset Quantinuum’s expanding cost structure. The operating loss widened by $79.9 million, while adjusted EBITDA loss increased by $35.2 million.

Because of Quantinuum’s Up-C structure, the $117.9 million consolidated GAAP net loss and the $0.46 Class A loss per share use different attribution bases. Net loss attributable to Quantinuum Inc. was $17.0 million, while $100.9 million was allocated to noncontrolling interests. Adjusted per-share results are presented on a fully distributed basis.

Business and Platform Momentum

Quantinuum signed the largest cloud agreement in its history, extending a relationship with a leading global financial institution through multiple years and including committed access to Nexus and Apollo. Other agreements covered cancer-therapy materials with a top-five global pharmaceutical company, superconducting materials with GE Vernova, and maritime logistics with Abu Dhabi Maritime Academy and Quincus.

The company also expanded distribution through an agreement with a major hyperscaler and launched an Oracle beta program for hybrid quantum-AI applications. However, Quantinuum did not disclose how much Q3 revenue came from these agreements.

Nexus adoption increased nearly 20% sequentially to 215 organizations. Job submissions during the 12 months through August 2026 were ten times the level recorded in the preceding 12-month period, providing a usage indicator beyond the quarter’s revenue.

On the technology roadmap, Quantinuum reported 99.9995% logical fidelity on Helios in October. Sol remained scheduled for the second half of 2027, with integration and assembly targeted for Q1 2027, while Apollo remained on track for 2029.

Gross Margin Improved, but Operating Investment Drove Wider Losses

The return to positive GAAP gross profit was meaningful, but its $3.0 million scale remained small relative to operating expenses. Research and development expense rose to $97.5 million from $42.4 million, sales and marketing expense increased to $14.9 million from $4.0 million, and general and administrative expense reached $22.1 million versus $5.3 million.

Total costs and expenses consequently increased to $141.9 million from $55.6 million. Stock-based compensation and related employer taxes accounted for $37.3 million of the adjustments between GAAP and adjusted net loss, while IPO and public-company readiness costs added $4.9 million. Even after excluding these items, the adjusted net loss widened, showing that the increase was not solely an accounting effect.

Financing Lifted Cash Despite Higher Operating Burn

Cash and cash equivalents ended September at $1.94 billion, up from $762.6 million at the end of 2025. The increase came primarily from financing rather than operations: financing activities provided $1.47 billion during the first nine months of 2026, including $1.63 billion of gross proceeds from common stock issuance.

For the nine months ended September 30, net cash used in operating activities increased to $229.9 million from $96.9 million. Capital expenditures were $64.7 million, compared with $61.0 million a year earlier. The nine-month GAAP net loss of $851.0 million was substantially larger than operating cash use, partly because it included $484.7 million of stock-based compensation and a $111.8 million noncash warrant fair-value loss.

Revenue Guidance

Quantinuum raised both ends of its full-year 2026 revenue range. The midpoint increased by $2.5 million, or approximately 8%, which management linked to technology progress, customer additions, and broader routes to market.

Recent Insider Transactions

The latest 10 reported transactions in the supplied insider data comprise one stock award and nine purchases. The nine purchases, all reported at $60 per share on June 5, totaled approximately $23.5 million and were recorded as direct holdings.

The supplied source also reported zero purchases and zero sales in its six-month summary, which conflicts with the June transaction list. That inconsistency limits conclusions from the summary and transaction data.

Risks Investors Need to Watch

• Losses and cash consumption remain substantial. Adjusted EBITDA loss widened during the quarter, while nine-month operating cash use more than doubled year over year.
• Revenue remains sensitive to contract timing. Quantinuum describes itself as an early commercial-stage company and said individual contract timing can affect period-to-period results.
• The technology roadmap requires continued execution. The commercial opportunity depends partly on delivering Sol in the second half of 2027 and Apollo in 2029 while meeting stated reliability and scale targets.
• Large noncash expenses complicate GAAP comparisons. Stock-based compensation and warrant remeasurement materially affected nine-month results, although adjusted losses also increased.

Summary

Quantinuum’s Q3 2026 results showed faster commercial activity, positive GAAP gross margin, and rising Nexus adoption, leading the company to raise its full-year revenue outlook. Those gains have not yet produced operating leverage: research, sales, and administrative spending expanded rapidly, adjusted losses widened, and operating cash use increased. The next points to monitor are progress toward the revised revenue range, conversion of commercial agreements into reported revenue, expense growth, and execution against the Sol and Apollo roadmaps.